Keyword: Momenta Pharmaceuticals
Pfizer reported earnings today, including good news for Sandoz and partner Momenta.
The Pfizer fill-finish plant whose manufacturing problems have gut-punched the expected approval of a generic of Teva’s long-acting Copaxone is a former Hospira plant with a history of issues.
The impending approval of Momenta's copy of Teva’s long-acting version of blockbuster Copaxone is now expected to be delayed.
It’s deja vu for Teva in a bad, bad way. A U.S. court struck down four patents on its long-acting version of multiple sclerosis star Copaxone, putting billions in sales at risk.
Three strikes for the patents on Teva’s long-acting Copaxone formula, but the branded drug isn’t out of the exclusivity game yet.
Bad news for Teva, much-needed good news for the embattled Mylan: The U.S. Patent and Trademark office’s review board struck down two patents on Teva’s new long-acting multiple sclerosis med Copaxone.
It didn’t take long for AbbVie to strike out against Amgen’s Humira biosimilar. Less than a month after an FDA panel gave the Humira copy a hearty thumbs-up, AbbVie has sued Amgen for patent infringement.
The Securities and Exchange Commission has nabbed another set of traders who allegedly profited off biopharma secrets. This time, their alleged source wasn't a pharma insider, but a former FDA official.